
Nicole Lamanna, MD, discusses the significance of the 3-year follow-up data from the MURANO trial in patients with relapsed/refractory chronic lymphocytic leukemia.

Your AI-Trained Oncology Knowledge Connection!


Published: December 14th 2018 | Updated: